News & Blog

May 01, 2024 | Blog Post
MEC in Q1 2024
May 01, 2024 | Press Release
AVILAR THERAPEUTICS TO PRESENT PRECLINICAL DATA FOR MTAC (M6PR TARGETING CHIMERA) EXTRACELLULAR PROTEIN DEGRADER PLATFORM AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS ANNUAL MEETING
April 17, 2024 | Press Release
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
April 16, 2024 | Press Release
Nobias Therapeutics Joins NVIDIA Inception Program for Startups
April 08, 2024 | Press Release
Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
April 08, 2024 | Press Release
Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy
March 28, 2024 | Press Release
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
March 05, 2024 | Press Release
Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
February 14, 2024 | Press Release
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
February 14, 2024 | Press Release
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead